Literature DB >> 2771513

Carbamyl phosphate synthetase and ornithine transcarbamylase activities in enzyme-deficient human liver measured by radiochromatography and correlated with outcome.

M Tuchman1, M Y Tsai, R A Holzknecht, S W Brusilow.   

Abstract

Sensitive and specific radiochromatographic methods to measure enzymatic activities of carbamyl phosphate synthetase I (CPS I) and ornithine transcarbamylase (OTC) were developed. The activities of these enzymes were assayed in frozen liver tissue obtained from 23 individuals with hyperammonemia caused by CPS I (five patients) and OTC deficiency (18 patients). In addition, livers of one aborted fetus with OTC deficiency and four normal individuals were studied. The assays use radioactive ornithine as a substrate followed by separation of citrulline formed in the reactions by HPLC and quantitation of the radioactivity in both amino acids by a radioactivity flow monitor or by a scintillation counter. Both CPS I and OTC assays were linear with respect to length of incubation time and concentration of tissue homogenate. The sensitivity of the methods allowed measurements of CPS I and OTC activities as low as 0.1 mumol/g/min on 5 mg of liver tissue and the diagnosis of CPS I or OTC deficiency could be established on as low as 0.5 and 0.05 mg of tissue, respectively. CPS I activity in different sections of four normal livers was 3.01 +/- 0.16 mumol/g/min (mean +/- SEM, n = 19) and OTC activity was 93.4 +/- 6.3 (mean +/- SEM, n = 19). Residual enzymatic activity could be detected and measured in the liver tissues of one of the five subjects with CPS I deficiency and in 14 of 19 subjects with OTC deficiency. OTC/CPS I activity ratio in normal liver tissue was 31.2 +/- 1.3 (mean +/- SEM, n = 19), whereas this ratio ranged from 343 to greater than 5000 in CPS I deficient livers and from less than 0.02 to 1.55 in OTC deficient livers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2771513     DOI: 10.1203/00006450-198907000-00021

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Prospective versus clinical diagnosis and therapy of acute neonatal hyperammonaemia in two sisters with carbamyl phosphate synthetase deficiency.

Authors:  M Tuchman; S M Mauer; R A Holzknecht; M L Summar; C L Vnencak-Jones
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 2.  Ornithine carbamoyl transferase deficiency: findings, models and problems.

Authors:  C Bachmann
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  Variable X-chromosome inactivation and enlargement of pericentral glutamine synthetase zones in the liver of heterozygous females with OTC deficiency.

Authors:  Dita Musalkova; Eva Sticova; Martin Reboun; Jitka Sokolova; Jakub Krijt; Jitka Honzikova; Jiri Gurka; Magdalena Neroldova; Tomas Honzik; Jiri Zeman; Milan Jirsa; Lenka Dvorakova; Martin Hrebicek
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

4.  Expression, purification, and characterization of recombinant human glutamine synthetase.

Authors:  C D Listrom; H Morizono; B S Rajagopal; M T McCann; M Tuchman; N M Allewell
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

5.  Enhanced production of arginine and urea by genetically engineered Escherichia coli K-12 strains.

Authors:  M Tuchman; B S Rajagopal; M T McCann; M H Malamy
Journal:  Appl Environ Microbiol       Date:  1997-01       Impact factor: 4.792

6.  Long-term outcomes in Ornithine Transcarbamylase deficiency: a series of 90 patients.

Authors:  Anais Brassier; Stephanie Gobin; Jean Baptiste Arnoux; Vassili Valayannopoulos; Florence Habarou; Manoelle Kossorotoff; Aude Servais; Valerie Barbier; Sandrine Dubois; Guy Touati; Robert Barouki; Fabrice Lesage; Laurent Dupic; Jean Paul Bonnefont; Chris Ottolenghi; Pascale De Lonlay
Journal:  Orphanet J Rare Dis       Date:  2015-05-10       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.